Medtronic PLC $MDT Shares Acquired by Okabena Investment Services Inc.

Okabena Investment Services Inc. lifted its holdings in Medtronic PLC (NYSE:MDT) by 394.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,059 shares of the medical technology company’s stock after buying an additional 12,811 shares during the period. Okabena Investment Services Inc.’s holdings in Medtronic were worth $1,529,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Corundum Trust Company INC purchased a new stake in shares of Medtronic in the third quarter valued at approximately $27,000. Valley Wealth Managers Inc. purchased a new stake in Medtronic in the 3rd quarter valued at $29,000. Delos Wealth Advisors LLC acquired a new stake in shares of Medtronic in the 2nd quarter worth $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medtronic during the 3rd quarter worth $33,000. Finally, Tripletail Wealth Management LLC acquired a new position in shares of Medtronic during the 3rd quarter valued at about $34,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
• Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
• Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
• Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

Medtronic Trading Up 0.6%

Shares of NYSE MDT opened at $97.60 on Friday. The company has a current ratio of 2.54, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $125.31 billion, a PE ratio of 27.19, a PEG ratio of 2.45 and a beta of 0.71. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The stock has a fifty day simple moving average of $98.93 and a 200-day simple moving average of $96.89.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the prior year, the company earned $1.38 EPS. Medtronic’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.26% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms recently issued reports on MDT. Robert W. Baird cut their price objective on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Needham & Company LLC reduced their price target on shares of Medtronic from $121.00 to $120.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Sanford C. Bernstein upped their price objective on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Finally, Leerink Partners cut their target price on Medtronic from $120.00 to $119.00 and set an “outperform” rating for the company in a research note on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.74.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).